Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2015-05-11FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for DIVALPROEX SODIUM (Divalproex Sodium) from Zydus Pharmaceuticals USA Inc., resulting in labeling…
-
FDA approval · 2015-05-08FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TROKENDI XR (topiramate extended-release) submitted by Supernus Pharmaceuticals, Inc. The ac…
-
FDA approval · 2015-05-01FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Biomedical Research Foundation of Northwest Louisiana)
FDA approved Fluorodeoxyglucose F-18 as a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging under an original ap…
-
FDA approval · 2015-04-30FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) filed by Viatris Specialty LLC.
-
CLINICAL_TRIALS research · 2015-04-29Clinical Trial Update: A Trial of Generic Substitution of Antiepileptic Drugs [Phase 4]
The document describes a Phase 4 clinical trial evaluating generic substitution of antiepileptic drugs for epilepsy, sponsored by the IRCCS …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-04-24FDA Approved: ZONISAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for Zonisamide by Sun Pharmaceutical Industries, Inc., indicating a regulatory modification for the …
-
CLINICAL_TRIALS research · 2015-04-24Clinical Trial Update: Epidiolex and Drug Resistant Epilepsy in Children
This entry notes an ongoing clinical trial evaluating Epidiolex (cannabidiol) for drug-resistant epilepsy in children, with Augusta Universi…
-
FDA approval · 2015-04-21FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2015-04-17FDA Approved: GABAPENTIN — Supplemental Application (Advagen Pharma Ltd)
FDA approved a supplemental application for gabapentin submitted by Advagen Pharma Ltd under the existing ANDA. This action updates the regu…
-
FDA approval · 2015-04-17FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved a supplemental application for gabapentin granules from Granules Pharmaceuticals Inc.
-
FDA approval · 2015-04-16FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN (extended phenytoin sodium), a new extended-release form from Viatris Specialty LLC.
-
FDA approval · 2015-04-16FDA Approved: PHENYTOIN INFATABS — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Phenytoin Infatabs (phenytoin) from Prasco Laboratories.
-
FDA approval · 2015-04-15FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for fosphenytoin sodium from Amneal Pharmaceuticals LLC (ANDA 078476).
-
FDA approval · 2015-04-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2015-04-14FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) filed by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy [Phase 2]
This update reports the completion of a Phase 2 controlled clinical trial evaluating cathodal transcranial direct current stimulation in pat…
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: Factors Associated With in Suboptimal Prescribing for Older Patients With Epilepsy
A completed VA-sponsored clinical trial update examining factors associated with suboptimal prescribing for older adults with epilepsy. The …
-
FDA approval · 2015-04-06FDA Approved: DIAZEPAM — Supplemental Application (Hospira, Inc.)
The FDA approved Hospira, Inc.'s supplemental application for diazepam (generic) under the ANDA.
-
FDA approval · 2015-03-31FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin filed by Quallent Pharmaceuticals Health LLC under ANDA200651.
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide
This update reports the completion of the WEUKBRE5557 IMI PROTECT Work Package 2 trial investigating the relationship between antiepileptic …
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis [NA]
A randomized trial evaluated albendazole in patients with epilepsy due to neurocysticercosis; the study has completed.
-
FDA approval · 2015-03-24FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL XR (lamotrigine) filed by GlaxoSmithKline LLC.
-
FDA approval · 2015-03-24FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) from GlaxoSmithKline LLC. The action indicates an approved change to …
-
CLINICAL_TRIALS trial_result · 2015-03-17Clinical Trial Update: Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy [Phase 3]
A Phase 3 trial comparing levetiracetam to standard antiepileptic drugs (carbamazepine and valproate) as monotherapy in newly diagnosed epil…
-
FDA approval · 2015-03-16FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Gabapentin from Actavis Pharma, Inc., resulting in approval of a generic gabapentin product.